Xenetic Biosciences (NASDAQ:XBIO) Share Price Passes Above 50 Day Moving Average – Here’s What Happened

Posted by Brian Himes on Aug 8th, 2026

Xenetic Biosciences, Inc. (NASDAQ:XBIO – Get Free Report)’s share price passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.89 and traded as high as $2.96. Xenetic Biosciences shares last traded at $2.85, with a volume of 18,955 shares trading hands.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Check Out Our Latest Report on XBIO

Xenetic Biosciences Stock Up 11.2%

The company’s 50 day moving average is $2.89 and its 200 day moving average is $2.81. The firm has a market capitalization of $7.26 million, a price-to-earnings ratio of -2.64 and a beta of 2.10.

Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter. The business had revenue of $0.66 million during the quarter. Xenetic Biosciences had a negative return on equity of 39.28% and a negative net margin of 70.03%.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC purchased a new stake in Xenetic Biosciences, Inc. (NASDAQ:XBIO – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences at the end of the most recent quarter. 15.12% of the stock is currently owned by hedge funds and other institutional investors.

Xenetic Biosciences Company Profile

(Get Free Report)

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.